AstraZeneca Pharma India has announced a key leadership appointment, naming Aditi Dayarus Mehta as Director. This strategic move brings experienced pharmaceutical industry talent to the company's board structure.

Leadership Appointment Details

The appointment of Mehta represents a significant addition to AstraZeneca Pharma India's leadership team. Her extensive background in the pharmaceutical sector positions her to contribute valuable insights to the company's strategic direction and operations.

Professional Background

Mehta brings substantial pharmaceutical industry experience to her new role, having spent more than a decade at Pfizer India. This extensive tenure at one of the world's leading pharmaceutical companies provides her with deep industry knowledge and operational expertise that will benefit AstraZeneca Pharma India's strategic initiatives.

Strategic Implications

The appointment reflects AstraZeneca Pharma India's focus on strengthening its leadership capabilities with professionals who possess relevant industry experience. Mehta's background in the pharmaceutical sector aligns with the company's operational requirements and strategic objectives in the Indian market.

AstraZeneca Pharma India Limited has strengthened its senior management team with the appointment of two experienced pharmaceutical professionals to key directorial positions. The Board of Directors approved these strategic appointments based on recommendations from the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI regulations.

Key Appointments

The company has made two significant appointments effective January 12, 2026:

Both positions are full-time employment roles that will contribute to the company's strategic business operations across critical therapeutic areas and market channels.

Ms. Aditi Dayarus Mehta - Oncology Leadership

Ms. Mehta brings over 15 years of pharmaceutical industry experience with expertise in Commercial Leadership, Strategy, and Change Management. Her professional journey includes:

• Previous Role: Business Unit Director at Pfizer India, leading the Innovative Vaccine portfolio
• Pfizer Experience: Over a decade across multiple roles including Oncology, Access, and Commercial Excellence
• Early Career: Business Analyst at Bristol Myers Squibb
• Education: Bachelor of Pharmacy (Gold Medallist) from K.M. Kundnani College of Pharmacy, Mumbai

Her track record demonstrates transformative commercial growth leadership rooted in equity and excellence values, with strategic orientation for leading collaborative teams.

Mr. Nitin Bindal - Institutional Business Expertise

Mr. Bindal contributes 17 years of diverse pharmaceutical industry experience across multiple therapeutic areas and functions:

Career Highlights:

• Bristol Myers Squibb: Business Unit Director – Oncology & Haematology, leading access and market penetration for immunotherapies across 20 indications
• Johnson & Johnson: Eight years in key roles including National Sales Head, Senior Marketing Manager in Oncology, and Neuroscience Business Unit leadership
• Additional Experience: Strategic and commercial roles at Novartis, Wockhardt, and Smart Analyst

Educational Background:

• Chemical Engineering degree from IIT Bombay
• Post Graduate Program in Management for Executives from UCLA Anderson School of Management, Los Angeles

Strategic Implications

These appointments underscore AstraZeneca Pharma India's commitment to strengthening its leadership in critical business areas. The oncology focus aligns with the growing importance of cancer therapeutics in the Indian pharmaceutical market, while the institutional business and public channels directorship addresses the company's distribution and access strategies.

Both appointees bring extensive experience from leading pharmaceutical companies including Pfizer, Bristol Myers Squibb, and Johnson & Johnson, providing valuable industry insights and established networks that will benefit AstraZeneca's operations in India.